Triangle Business Journal by Lauren K. Ohnesorge, Staff Writer
Durham-based Bioptigen Inc. has received a medical device license from Health Canada to begin marketing its hand-held Envisu SDOIS C2200 and C2300 ophthalmic imaging systems for patient use in Canada.
Marketing in the United States is still pending FDA approval, but President and CEO Eric Buckland said the company is prepared to start selling and shipping to clinical users in Canada now. The handheld Envisu systems allow physicians to scan patients’ eyes without having to bring a patient to the scanner, which is particularly helpful when treating children.
Bioptigen employs 20 people locally and is moving forward with additional plans for new technology.